跳转至内容
Merck
CN

SML1974

CBLC000 trifluoroacetate

≥95% (HPLC)

别名:

9H-Carbazole-9-ethanamine, N,N-diethyl-3,6-dinitro- trifluoroacetate, Curaxin CBLC000 trifluoroacetate, N,N-Diethyl-3,6-dinitro-9H-carbazole-9-ethanamine trifluoroacetate

登录 查看组织和合同定价。

选择尺寸

变更视图

关于此项目

经验公式(希尔记法):
C18H20N4O4 · C2HF3O2
化学文摘社编号:
分子量:
470.40
UNSPSC Code:
12352200
NACRES:
NA.77
Assay:
≥95% (HPLC)
Form:
powder
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助


assay

≥95% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

2-8°C

SMILES string

CCN(CC)CCN1C2=C(C=C([N+]([O-])=O)C=C2)C3=C1C=CC([N+]([O-])=O)=C3.FC(F)(C(O)=O)F

InChI

1S/C18H20N4O4.C2HF3O2/c1-3-19(4-2)9-10-20-17-7-5-13(21(23)24)11-15(17)16-12-14(22(25)26)6-8-18(16)20;3-2(4,5)1(6)7/h5-8,11-12H,3-4,9-10H2,1-2H3;(H,6,7)

InChI key

VFGJIBCWHYFSHE-UHFFFAOYSA-N

Biochem/physiol Actions

CBLC000 is a potent inhibitor of FACT (facilitates chromatin transcription) complex that activates p53 and suppresses NF-kB without genotoxicity. CBLC000 induces chromatin trapping of FACT both in vitro and in vivo. CBLC000 exhibits brad anticancer activity. CBLC000 analog clinical candidate CBL0137 decreases self-renewal of GBM stem cells (GSC).
Potent inhibitor of FACT complex that activates p53 and suppresses NF-kB without genotoxicity


pictograms

Exclamation mark

signalword

Warning

Hazard Classifications

Acute Tox. 4 Oral - Aquatic Chronic 4 - Skin Irrit. 2

存储类别

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

法规信息

新产品

此项目有



历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库



Josephine Kam Tai Dermawan et al.
Cancer research, 76(8), 2432-2442 (2016-02-28)
The nearly universal recurrence of glioblastoma (GBM) is driven in part by a treatment-resistant subpopulation of GBM stem cells (GSC). To identify improved therapeutic possibilities, we combined the EGFR/HER2 inhibitor lapatinib with a novel small molecule, CBL0137, which inhibits FACT
Alexander V Gasparian et al.
Science translational medicine, 3(95), 95ra74-95ra74 (2011-08-13)
Effective eradication of cancer requires treatment directed against multiple targets. The p53 and nuclear factor κB (NF-κB) pathways are dysregulated in nearly all tumors, making them attractive targets for therapeutic activation and inhibition, respectively. We have isolated and structurally optimized



全球贸易项目编号

货号GTIN
SML1974-5MG04061832639437
SML1974-25MG04061832639420